Moti N Ramgopal MD FACP FIDSA
Consultant Physician /Director Associates in Infectious Disease Director/Founder Midway Immunology and Research Center Asst.Professor Medicine Florida State University Medical School
Join to View Full Profile
356 E Midway RdFort Pierce, FL 34982
Phone+1 772-464-9746
Fax+1 772-464-9750
Dr. Ramgopal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Moti Ramgopal is an infectious disease specialist in Fort Pierce, FL and is affiliated with multiple hospitals in the area, including Lawnwood Regional Medical Center & Heart Institute, Port St. Lucie Hospital, and St. Lucie Medical Center. He received his medical degree from University of the West Indies Faculty of Medical Sciences and has been in practice 28 years. He is experienced in travel and tropical medicine, infectious disease, osteomyelitis, prevertebral infection, and mandibular space infection.
Education & Training
University of Miami/Jackson Health SystemFellowship, Infectious Disease, 1995 - 1997
Bon Secours HospitalResidency, Internal Medicine, 1992 - 1995
University of the West Indies Faculty of Medical SciencesClass of 1989
Certifications & Licensure
FL State Medical License 1996 - 2026
MI State Medical License 1994 - 1998
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
Publications & Presentations
PubMed
- Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV.Moti Ramgopal, Dylan J Mezzio, Keith Dunn, Shan-Yu Liu, Damemarie Paul
AIDS and Behavior. 2025-05-01 - Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.Eric S Daar, Chloe Orkin, Paul E Sax, Debbie Hagins, Anton Pozniak
AIDS Research and Therapy. 2025-04-07 - 13 citationsTwice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.Colleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, Anchalee Avihingsanon, Paul Benson
The New England Journal of Medicine. 2025-04-03
Press Mentions
Five Years After COVID-19, Are We Ready for a New Pandemic? | OpinionApril 7th, 2025- COVID Surge: What if We Had Just Listened to Local Doctors Pierone, Ramgopal? | OpinionAugust 6th, 2021
- The Science of COVID-19: COVID-19 and Treatment of AdultsMarch 8th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
